gc101
Advanced Solid Tumor
Shanghai Juncell Therapeuticsgene_therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 59/ 100
Competitive context
547 Active assets in the Advanced Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Toripalimab Nanjing Immunophage Biotech Co., Ltd | Phase 2 | B |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | B |
Pyrotinib LaNova Medicines Limited | Phase 3 | B |
rc48-adc LaNova Medicines Limited | Phase 3 | B |
Epirubicin InSilico Medicine Hong Kong Limited | Phase 3 | B |
View all 50 →
Same molecule, other indications
gc101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →